Title |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2014
|
DOI | 10.1002/14651858.cd007744.pub2 |
Pubmed ID | |
Authors |
Xin‐Pu Miao, Jian‐Sheng Li, Qin Ouyang, Ren‐Wei Hu, Yan Zhang, Hui‐Yan Li |
Abstract |
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammatory pain and swelling in inflammatory bowel disease (IBD) patients with rheumatological manifestations. While these drugs effectively reduce musculoskeletal pain and stiffness, long-term use is limited by gastrointestinal (GI) adverse effects (AEs) and disease exacerbation. As an alternative to NSAIDs, selective cyclooxygenase 2 (COX-2) inhibitors were developed to improve GI safety and tolerability. COX-2 inhibitors include drugs such as celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib. Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity. However, celecoxib and etoricoxib continue to be available for use in many countries. Several studies have examined whether COX-2 inhibitors can be safely used for the treatment of rheumatological manifestations of IBD with inconsistent results. Some investigators report acceptable safety profiles associated with these drugs while others found that COX-2 inhibitors are associated with high rates of disease exacerbation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 20% |
France | 1 | 20% |
Colombia | 1 | 20% |
United States | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 1% |
Unknown | 155 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 27 | 17% |
Researcher | 20 | 13% |
Student > Bachelor | 14 | 9% |
Student > Ph. D. Student | 13 | 8% |
Other | 8 | 5% |
Other | 26 | 17% |
Unknown | 49 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 54 | 34% |
Nursing and Health Professions | 14 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
Agricultural and Biological Sciences | 5 | 3% |
Psychology | 5 | 3% |
Other | 19 | 12% |
Unknown | 54 | 34% |